Restricted accessReview articleFirst published online 2026-3
The resurgence of Tuberculosis in the United States: Health implications,pathophysiological and clinical insights,emerging trends,strategic responses,and post-COVID-19 challenges
To address the challenges of tuberculosis (TB) control in the United States post-COVID-19, focusing on high-risk populations, current diagnostic and treatment strategies, and the importance of addressing clinical and social determinants of health to achieve TB elimination goals.
Methods
A review of the latest evidence-based guidelines and literature on TB diagnostics, treatment regimens, and latent TB infection (LTBI) management was conducted. Key public health challenges and interventions targeting socioeconomic disparities, stigma, and healthcare access among high-risk populations were analyzed.
Results
High-risk groups, including immigrants and ethnic minorities, continue to bear a disproportionate burden of TB due to socioeconomic disparities and comorbidities. Advancements in diagnostic modalities and treatment regimens offer promising outcomes, but gaps remain in LTBI screening and management. Addressing social determinants, such as healthcare access and stigma, is essential for enhancing TB control efforts.
Discussion
Effective TB elimination requires collaborative efforts among healthcare professionals, policymakers, and communities to implement evidence-based strategies. Prioritizing both clinical precision and social interventions is critical for overcoming barriers and achieving national TB control and elimination goals.
BaiWAmeyawEK. Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021. BMC Public Health2024; 24: 12.
2.
GolettiDAl-AbriSMiglioriGB, et al.World Tuberculosis Day 2024 theme “Yes! We can end TB” can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease. Int J Infect Dis2024; 141. doi:10.1016/j.ijid.2024.106993
3.
AlsayedSSRGunosewoyoH. Tuberculosis: pathogenesis, current treatment regimens and new drug targets. Int J Mol Sci2023; 24: 5202.
4.
JainVKIyengarKPSamyDA, et al.Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr Clin Res Rev2020; 14: 1439–1443.
5.
FilardoTDFengPJPrattRH, et al.Tuberculosis — United States, 2021. MMWR Morb Mortal Wkly Rep2022; 71: 441–446.
RajaramMVSArnettEAzadAK, et al.M. tuberculosis -initiated human mannose receptor signaling regulates macrophage recognition and vesicle trafficking by FcRγ-chain, Grb2, and SHP-1. Cell Rep2017; 21: 126–140.
20.
StammCECollinsACShilohMU. Sensing of Mycobacterium tuberculosis and consequences to both host and bacillus. Immunol Rev2015; 264: 204–219.
21.
ZuñigaJTorres-GarcíaDSantos-MendozaT, et al.Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol2012; 2012: 193923.
22.
KumarVAbbasAKFaustoN, et al.Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier Health Sciences, 2014.
AiJWRuanQLLiuQH, et al.Updates on the risk factors for latent tuberculosis reactivation and their management. Emerg Microbes Infect2016; 5: 10.
26.
RestrepoCSKatreRMumbowerA. Imaging manifestations of thoracic Tuberculosis. Radiol Clin North Am2016; 54: 453–473.
27.
HuangYAiLWangX, et al.Review and updates on the diagnosis of Tuberculosis. J Clin Med2022; 11: 5826.
28.
Baquero-ArtigaoFDel RosalTFalcón-NeyraL, et al.Update on the diagnosis and treatment of tuberculosis. An Pediatría Engl Ed2023; 98: 460–469.
29.
HickeyAJCummingsMJZafariZ, et al.Evaluation of screening strategies for pulmonary tuberculosis among hospitalized patients in a low-burden setting: cost-effectiveness of GeneXpert MTB/RIF compared to smear microscopy. Infect Control Hosp Epidemiol2022; 43: 892–897.
30.
de Lima CorvinoDFShresthaSHollingsheadCM, et al.Tuberculosis Screening. In: StatPearls. StatPearls Publishing, http://www.ncbi.nlm.nih.gov/books/NBK448205/ (2024, accessed 9 May 2024).
31.
LewinsohnDMLeonardMKLoBuePA, et al.Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis2017; 64: e1–e33.
32.
OrganizationWH. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment. World Health Organization, 2022.
WinstonCAMarksSMCarrW. Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States. Emerg Infect Dis2023; 29. doi:10.3201/eid2910.230314
40.
VermaSPachecoCCarterEJ, et al.Latent Tuberculosis infection treatment outcomes in an at-risk underserved population in Rhode Island. J Prim Care Community Health2022; 13: 215013192211111.
41.
MiramontesRHillANYelk WoodruffRS, et al.Tuberculosis infection in the United States: prevalence estimates from the national health and nutrition examination survey, 2011-2012. PLOS ONE2015; 10: e0140881.
42.
MirzazadehAKahnJGHaddadMB, et al.State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. PLOS ONE2021; 16: e0249012.
43.
HaddadMBRazKMLashTL, et al.Simple estimates for local prevalence of latent Tuberculosis infection, United States, 2011–2015. Emerg Infect Dis2018; 24: 1930–1933.
44.
LiuYPharesCRPoseyDL, et al.Tuberculosis among newly arrived immigrants and refugees in the United States. Ann Am Thorac Soc2020; 17: 1401–1412.
HargreavesJRBocciaDEvansCA, et al.The social determinants of Tuberculosis: from evidence to action. Am J Public Health2011; 101: 654–662.
47.
LippincottCKPerryAMunkE, et al.Tuberculosis treatment adherence in the era of COVID-19. BMC Infect Dis2022; 22: 00.
48.
KaufmannSHE. Vaccine development against tuberculosis before and after COVID-19. Front Immunol2023; 14: 1273938.
49.
HolzmanSBZenilmanAShahM. Advancing patient-centered care in Tuberculosis management: a mixed-methods appraisal of video directly observed therapy. Open Forum Infect Dis2018; 5: ofy046.
50.
DonahueMLEberlyMDRajnikM. Tele-TB: using TeleMedicine to increase access to directly observed therapy for latent tuberculosis infection. Mil Med2021; 186: 25–31.
51.
World Health Organization. World Health Organization; Geneva: 2022. WHO consolidated guidelines on tuberculosis. module 4: treatment - drug-resistant tuberculosis treatment 2022 update (accessed 4 July 2023).
52.
SpringerYPKammererJSFelixD, et al.Using Geographic Disaggregation to Compare Tuberculosis Epidemiology Among American Indian and Alaska Native Persons—USA, 2010–2020. J Racial Ethn Health Disparities2024. doi:10.1007/s40615-024-01919-z
53.
SantosJALeiteASoaresP, et al.Delayed diagnosis of active pulmonary tuberculosis - potential risk factors for patient and healthcare delays in Portugal. BMC Public Health2021; 21: 2178.
54.
TeoAKJSinghSRPremK, et al.Duration and determinants of delayed tuberculosis diagnosis and treatment in high-burden countries: a mixed-methods systematic review and meta-analysis. Respir Res2021; 22: 51.
55.
DatikoDGJereneDSuarezP. Stigma matters in ending tuberculosis: nationwide survey of stigma in Ethiopia. BMC Public Health2020; 20: 90.
56.
ChangSHCataldoJK. A systematic review of global cultural variations in knowledge, attitudes and health responses to tuberculosis stigma. Int J Tuberc Lung Dis2014; 18: 168-iv.
57.
CraigGMDaftaryAEngelN, et al.Tuberculosis stigma as a social determinant of health: a systematic mapping review of research in low incidence countries. Int J Infect Dis2017; 56: 90–100.
FuadyAArifinBYunitaF, et al.Stigma towards people with tuberculosis: a cross-cultural adaptation and validation of a scale in Indonesia. BMC Psychol2023; 11: 12.
60.
CourtwrightATurnerAN. Tuberculosis and stigmatization: pathways and interventions. Public Health Rep2010; 125: 34–42.
61.
BarkCMBoomWHFurinJJ. More tailored approaches to Tuberculosis treatment and prevention. Annu Rev Med2024; 75: 177–188.
62.
BouzeyenRJavidB. Therapeutic vaccines for Tuberculosis: an overview. Front Immunol2022; 13: 878471.
WorthamJMHaddadMBStewartRJ, et al.Second nationwide Tuberculosis outbreak caused by bone allografts containing live cells — United States, 2023. MMWR Morb Mortal Wkly Rep2024; 72: 1385–1389.
CalderonJSPerryKEThiSS, et al.Innovating tuberculosis prevention to achieve universal health coverage in the Philippines. Lancet Reg Health - West Pac2022; 29: 100609.
